Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback